Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024 16:15 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
September 12, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Upcoming Investor Conferences
September 04, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 13, 2024 16:08 ET
|
Solid Biosciences Inc.
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4...
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 05, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2024 16:19 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Joins the Russell 3000® Index
July 01, 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024 16:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...